A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer Med, 13
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Kent D. et al, (2024), Hepatology
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nat Commun, 15
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R. et al, (2024), J Immunother Cancer, 12
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages.
Navarro-Guerrero E. et al, (2024), STAR Protoc, 5
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Bešević J. et al, (2023), J Epidemiol Community Health
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
Athanasiadis P. et al, (2023), iScience, 26
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Buckell J. et al, (2023), Sci Rep, 13
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J. et al, (2023), Nat Commun, 14
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.
Emmenegger M. et al, (2023), iScience
Longitudinal characterization of TK6 cells sequentially adapted to animal product-free, chemically defined culture medium: considerations for genotoxicity studies.
Perez-Diaz N. et al, (2023), Front Toxicol, 5
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk.
Rottner AK. et al, (2022), Nat Genet
Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom.
Vihta KD. et al, (2022), Clin Infect Dis
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
Wei J. et al, (2022), Nat Commun, 13
Automated 96-well format high throughput colony formation assay for siRNA library screen.
Hatch SB. et al, (2022), STAR Protoc, 3
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
Wei J. et al, (2022), Nat Med, 28, 1072 - 1082
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
Arnaiz E. et al, (2021), BMC Cancer, 21